Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06038-7 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Fabio Efficace und 15 weiteren Autor:innen. Beteiligte Einrichtung: Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy. f.efficace@gimema.it. Hauptthemen laut MEDLINE: Arsenic Trioxide, Leukemia, Promyelocytic, Acute, Quality of Life. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Very limited evidence is available on the long-term health-related quality of life (HRQoL) of patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide (ATO). We performed an extended follow-up of the APL0406 randomized controlled trial to investigate HRQoL of patients treated with either ATO or chemotherapy. A secondary objective was to describe the prevalence of clinically important problems and symptoms of these patients by type of treatment. Overall, 117 patients were included in this analysis after a median follow-up of 10 years (IQR 8-11) since diagnosis. Of these, 60 (51.3%) were treated with ATO, and 57 (48.7%) with chemotherapy. A statistically significant and clinically relevant difference, favoring patients treated with ATO, was found in 2 of the 3 main prespecified EORTC QLQ-C30 scales, that is, cognitive functioning (∆ = 7.7; 95% CI 0.5 to 14.9; p = 0.036) and fatigue (∆ = -9.4; 95% CI -17.9 to -0.8; p = 0.031). The prevalence of clinically important problems and symptoms tended to be slightly higher in patients treated with chemotherapy. These findings suggest that previously observed HRQoL advantages of ATO therapy of patients included in the APL0406 trial are sustained over the long-term period. This study was registered at ClinicalTrials.gov (NCT03096496).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy. f.efficace@gimema.it.
- Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
- Hematology, Department of Translational and Precision Medicine, University Sapienza Rome, Roma, Italy.
- Division of Hematology, Vicenza, Italy.
- Hematology and Bone Marrow Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
- Hematology, ASST-Spedali Civili, Brescia, Italy.
Zitieren
APA
Efficace, F., Sparano, F., Breccia, M., Greco, C., Carluccio, P., Borlenghi, E., Salutari, P., Levato, L., Baldi, T., Mancini, V., Finizio, O., Autore, F., Fazi, P., Platzbecker, U., Vignetti, M., & Voso, M. T. (2024). Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial. Annals of Hematology. https://doi.org/10.1007/s00277-024-06038-7
Vancouver
Efficace F, Sparano F, Breccia M, Greco C, Carluccio P, Borlenghi E, et al. Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial. Annals of Hematology. 2024. doi:10.1007/s00277-024-06038-7
BibTeX
@article{Efficace2024,
author = {Efficace, Fabio and Sparano, Francesco and Breccia, Massimo and Greco, Corinna and Carluccio, Paola and Borlenghi, Erika and Salutari, Prassede and Levato, Luciano and Baldi, Thomas and Mancini, Valentina and Finizio, Olimpia and Autore, Francesco and Fazi, Paola and Platzbecker, Uwe and Vignetti, Marco and Voso, Maria Teresa},
title = {Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06038-7}
}
EUVIMED